The Italian FFI was developed according to

The Italian FFI was developed according to Selleckchem PP2 the recommended forward/backward translation protocol and evaluated in patients with foot and ankle diseases. Feasibility, reliability [intraclass correlation coefficient (ICC)], internal consistency [Cronbach's alpha (CA)], construct validity (correlation with the SF-36 and a visual analogue scale (VAS) assessing for pain), responsiveness to surgery were assessed. The standardized effect size and standardized response mean were also evaluated.

A total of 89 patients

were recruited (mean age 51.8 +/- A 13.9 years, range 21-83). The Italian version of the FFI consisted in 18 items separated into a pain and disability subscales. CA value was 0.95 for both the subscales. The reproducibility was good with an ICC of 0.94 and 0.91 for pain and disability subscales, respectively. A strong correlation was found between the FFI and the scales of the SF-36 and the VAS with related content, particularly in the areas of physical function and pain was observed indicating good construct validity. After surgery, the mean FFI improved from 55.9 +/- A 24.8 to 32.4 +/- A 26.3 for the pain subscale and from 48.8 +/- A 28.8 to 24.9 +/- A 23.7 for the disability subscale (P < 0.01).

The Italian version of the FFI showed satisfactory psychometric properties in Italian Duvelisib patients with foot and ankle diseases. Further testing in different BKM120 purchase and larger samples is required

in order to ensure the validity and reliability of this score.”
“Pompe disease or glycogen-storage disease type 2 (GSD2, OMIM 232300) is an autosomal recessive disorder caused by mutations in the acid alpha-glucosidase gene. Late-onset GSD2 resembles some limb-girdle and Becker muscular dystrophies. The screening of GSD2 through the measurement of acid alpha-glucosidase activity in dried blood spots was applied to a selected sample of 5 Mexican patients with proximal myopathies of unknown

etiology. Only 1 male patient showed a low level of acid alpha-glucosidase activity and a compound heterozygote genotype for the c.-32-13T > G splicing mutation present in most white late-onset Pompe disease cases and the novel mutation p.C558S. To our knowledge, this is the first report of a Mexican patient with late-onset GSD2. The identification of c.-32-13T > G in our patient could reflect the genetic contribution of European ancestry to the Mexican population. The enzymatic screening of GSD2 could be justified in patients with myopathies of unknown etiology.”
“The Overactive Bladder Symptom Score (OABSS) is comprised of 4 items with a single total score for quantification of OAB symptoms and has been reported as sensitive to treatment-related changes. The aim of this study was to assess the psychometric properties of the Korean version in patients with OAB symptoms.

Two prospective trials were conducted at two teaching hospitals.

Comments are closed.